A Phase 2/3 interventional study of cefdinir in Acute Otitis Media, sponsored by Abbott. Completed at 22 sites in 7 countries. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2008-03-27.
Sponsored by Abbott · Phase 2/3, Interventional, and Treatment
To evaluate the safety and efficacy of cefdinir oral suspension in children between 6 months and 4 years of age, with acute otitis media, who are at risk of persistent or recurrent otitis media.
246 studies on the registry are indexed under Otitis; 21 are open to participants now.
This study's enrollment of 447 is above the median of 126 across 173 interventional studies indexed under Otitis.
Browse Otitis studies →Abbott is the lead sponsor of 350 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: cefdinir
cefdinir oral suspension, 25 mg/kg once daily for 10 days
Also known as: ABT-198, Omnicef, cefdinir
Bacteriological Response
Time frame: 30 days
Clinical response
Time frame: 30 days
Change in the otoscopic findings
Time frame: 30 days
Physical exam; Vital signs; Use of concomitant medications
Time frame: 59 days
Adverse events assessment
Time frame: 45 days with follow-up to a satisfactory conclusion
Laboratory evaluations
Time frame: 30 days
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abbott